3 results
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
Primary- To determine the validity of home-based self-monitoring of VC in patients with MND.Secondary- To determine the reliability of home-based self-monitoring of VC in patients with MND.- To evaluate the feasibility of 4-weekly home-based self-…
Primary:To compare the efficacy of abrocitinib 200 mg once daily (QD) versus dupilumab (as per label guidelines) in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD).Key SecondaryTo compare the efficacy…